Anxiety disorders, encompassing generalized anxiety disorder, social anxiety, panic disorder, and specific phobias, are pervasive mental health conditions associated with significant distress and functional impairment. A comprehensive search was conducted from July 2024 to December 2025 across PubMed, Scopus, and Embase from inception to the present. According to the document on metabolomic markers in disorders of anxiety, these disorders arise from a complex interaction of genetic, neurobiological, and psychosocial factors. Key challenges in managing anxiety disorders include accurate diagnosis and distinguishing anxiety symptoms from overlapping medical conditions such as asthma, atrial fibrillation, and hyperthyroidism. The present investigation is narrative review. It provides an informative, valuable narrative review of the history, abnormalities, and roles of neurotransmitters—norepinephrine, serotonin, dopamine, and GABA—and the involvement of brain structures such as the amygdala and limbic system, which underscore the neurobiological basis of anxiety. Current treatments concentrate on a combination of Selective serotonin reuptake Inhibitors (SSRIs), serotonin-nor-epinephrine reuptake Inhibitors (SNRIs), and benzodiazepines, alongside cognitive behavioural remedy (CBT). However, these approaches are not universally effective, and issues such as drug dependency and side effects remain critical obstacles. Emerging research in metabolomics offers potential for identifying biomarkers that could improve diagnostic accuracy and treatment personalization. Integrating metabolomic insights with traditional and complementary therapies may enhance treatment outcomes. Addressing these multifaceted challenges requires interdisciplinary collaboration to advance research and develop tailored, effective strategies for managing anxiety disorders in diverse patient populations. Keywords: Anxiety, Anxiety disorders, Metabolomic markers, Biomarkers
Gupta et al. (Sun,) studied this question.